Cost effectiveness of peginterferon alfa-2B combined with ribavirin for the treatment of chronic hepatitis C in Brazil
Autor(a) principal: | |
---|---|
Data de Publicação: | 2009 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | http://repositorio.unifesp.br/handle/11600/5059 http://dx.doi.org/10.1590/S1413-86702009000300007 |
Resumo: | The treatment of chronic hepatitis C (CHC) with peginterferon alpha-2b/ribavirin (PegIFN + Rib) produced larger sustained viral response (SVR) compared to the conventional (non-pegylated) interferon/ribavirin (IFN + Rib), but its cost-effectiveness was not assessed in Brazil. We developed a Markov model to mirror the natural disease history and cohorts of patients with hepatitis C virus (HCV), that received PegIFN + Rib or IFN + Rib treatment for 48 or 24 weeks, according to viral genotype and liver histology. The SVRs for the treatments PegIFN + Rib and IFN + Rib were respectively 48% and 34% (genotype 1), and 88% and 80% (genotype non-1). Three Delphi panels were conducted with hepatologists and intensivists, and another one with oncologists. The costs are expressed in 2006 Brazilian Reais (R$) and the benefits were discounted at 3%. In genotype 1 HCV patients, PegIFN + Rib increases the life expectancy (LE) in 0.51 year, and the quality-adjusted life years (QALY) in 0.78, as compared to IFN + Rib. In genotype non-1 HCV patients, PegIFN + Rib increases the LE in 0.29 years and the QALY in 0.44 years, as compared to IFN + Rib. The incremental cost-effectiveness rate, considering all the genotypes, was of R$19,848.34 per QALY. Peginterferon alpha-2b with ribavirin is a cost-effective therapy for the treatment of naïve CHC adult patients compared to the interferon alpha-2b and ribavirin regime, irrespective of the viral genotype. |
id |
UFSP_5eb849bb099a08a95cde5cb457185faa |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br:11600/5059 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Fonseca, Marcelo Cunio Machado [UNIFESP]Araujo, Gabriela Tannus Branco de [UNIFESP]Araujo, Denizar Vianna [UNIFESP]Universidade Federal de São Paulo (UNIFESP)State University of Rio de Janeiro2015-06-14T13:39:13Z2015-06-14T13:39:13Z2009-06-01Brazilian Journal of Infectious Diseases. Brazilian Society of Infectious Diseases, v. 13, n. 3, p. 191-199, 2009.1413-8670http://repositorio.unifesp.br/handle/11600/5059http://dx.doi.org/10.1590/S1413-86702009000300007S1413-86702009000300007.pdfS1413-8670200900030000710.1590/S1413-86702009000300007WOS:000275105600007The treatment of chronic hepatitis C (CHC) with peginterferon alpha-2b/ribavirin (PegIFN + Rib) produced larger sustained viral response (SVR) compared to the conventional (non-pegylated) interferon/ribavirin (IFN + Rib), but its cost-effectiveness was not assessed in Brazil. We developed a Markov model to mirror the natural disease history and cohorts of patients with hepatitis C virus (HCV), that received PegIFN + Rib or IFN + Rib treatment for 48 or 24 weeks, according to viral genotype and liver histology. The SVRs for the treatments PegIFN + Rib and IFN + Rib were respectively 48% and 34% (genotype 1), and 88% and 80% (genotype non-1). Three Delphi panels were conducted with hepatologists and intensivists, and another one with oncologists. The costs are expressed in 2006 Brazilian Reais (R$) and the benefits were discounted at 3%. In genotype 1 HCV patients, PegIFN + Rib increases the life expectancy (LE) in 0.51 year, and the quality-adjusted life years (QALY) in 0.78, as compared to IFN + Rib. In genotype non-1 HCV patients, PegIFN + Rib increases the LE in 0.29 years and the QALY in 0.44 years, as compared to IFN + Rib. The incremental cost-effectiveness rate, considering all the genotypes, was of R$19,848.34 per QALY. Peginterferon alpha-2b with ribavirin is a cost-effective therapy for the treatment of naïve CHC adult patients compared to the interferon alpha-2b and ribavirin regime, irrespective of the viral genotype.Federal University of São PauloState University of Rio de JaneiroUNIFESP, EPM, São Paulo, BrazilSciELO191-199engBrazilian Society of Infectious DiseasesBrazilian Journal of Infectious DiseasesHepatitis Ccost-benefit analysiseffectivenessinterferonsCost effectiveness of peginterferon alfa-2B combined with ribavirin for the treatment of chronic hepatitis C in Brazilinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESPORIGINALS1413-86702009000300007.pdfapplication/pdf129423${dspace.ui.url}/bitstream/11600/5059/1/S1413-86702009000300007.pdf9288cf4a85f38c3c07f6f1715e801e78MD51open accessTEXTS1413-86702009000300007.pdf.txtS1413-86702009000300007.pdf.txtExtracted texttext/plain42616${dspace.ui.url}/bitstream/11600/5059/2/S1413-86702009000300007.pdf.txtff9be2146f93f3a75c381b3585a20903MD52open access11600/50592023-02-14 13:42:51.015open accessoai:repositorio.unifesp.br:11600/5059Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestopendoar:34652023-05-25T12:30:02.186262Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.en.fl_str_mv |
Cost effectiveness of peginterferon alfa-2B combined with ribavirin for the treatment of chronic hepatitis C in Brazil |
title |
Cost effectiveness of peginterferon alfa-2B combined with ribavirin for the treatment of chronic hepatitis C in Brazil |
spellingShingle |
Cost effectiveness of peginterferon alfa-2B combined with ribavirin for the treatment of chronic hepatitis C in Brazil Fonseca, Marcelo Cunio Machado [UNIFESP] Hepatitis C cost-benefit analysis effectiveness interferons |
title_short |
Cost effectiveness of peginterferon alfa-2B combined with ribavirin for the treatment of chronic hepatitis C in Brazil |
title_full |
Cost effectiveness of peginterferon alfa-2B combined with ribavirin for the treatment of chronic hepatitis C in Brazil |
title_fullStr |
Cost effectiveness of peginterferon alfa-2B combined with ribavirin for the treatment of chronic hepatitis C in Brazil |
title_full_unstemmed |
Cost effectiveness of peginterferon alfa-2B combined with ribavirin for the treatment of chronic hepatitis C in Brazil |
title_sort |
Cost effectiveness of peginterferon alfa-2B combined with ribavirin for the treatment of chronic hepatitis C in Brazil |
author |
Fonseca, Marcelo Cunio Machado [UNIFESP] |
author_facet |
Fonseca, Marcelo Cunio Machado [UNIFESP] Araujo, Gabriela Tannus Branco de [UNIFESP] Araujo, Denizar Vianna [UNIFESP] |
author_role |
author |
author2 |
Araujo, Gabriela Tannus Branco de [UNIFESP] Araujo, Denizar Vianna [UNIFESP] |
author2_role |
author author |
dc.contributor.institution.none.fl_str_mv |
Universidade Federal de São Paulo (UNIFESP) State University of Rio de Janeiro |
dc.contributor.author.fl_str_mv |
Fonseca, Marcelo Cunio Machado [UNIFESP] Araujo, Gabriela Tannus Branco de [UNIFESP] Araujo, Denizar Vianna [UNIFESP] |
dc.subject.eng.fl_str_mv |
Hepatitis C cost-benefit analysis effectiveness interferons |
topic |
Hepatitis C cost-benefit analysis effectiveness interferons |
description |
The treatment of chronic hepatitis C (CHC) with peginterferon alpha-2b/ribavirin (PegIFN + Rib) produced larger sustained viral response (SVR) compared to the conventional (non-pegylated) interferon/ribavirin (IFN + Rib), but its cost-effectiveness was not assessed in Brazil. We developed a Markov model to mirror the natural disease history and cohorts of patients with hepatitis C virus (HCV), that received PegIFN + Rib or IFN + Rib treatment for 48 or 24 weeks, according to viral genotype and liver histology. The SVRs for the treatments PegIFN + Rib and IFN + Rib were respectively 48% and 34% (genotype 1), and 88% and 80% (genotype non-1). Three Delphi panels were conducted with hepatologists and intensivists, and another one with oncologists. The costs are expressed in 2006 Brazilian Reais (R$) and the benefits were discounted at 3%. In genotype 1 HCV patients, PegIFN + Rib increases the life expectancy (LE) in 0.51 year, and the quality-adjusted life years (QALY) in 0.78, as compared to IFN + Rib. In genotype non-1 HCV patients, PegIFN + Rib increases the LE in 0.29 years and the QALY in 0.44 years, as compared to IFN + Rib. The incremental cost-effectiveness rate, considering all the genotypes, was of R$19,848.34 per QALY. Peginterferon alpha-2b with ribavirin is a cost-effective therapy for the treatment of naïve CHC adult patients compared to the interferon alpha-2b and ribavirin regime, irrespective of the viral genotype. |
publishDate |
2009 |
dc.date.issued.fl_str_mv |
2009-06-01 |
dc.date.accessioned.fl_str_mv |
2015-06-14T13:39:13Z |
dc.date.available.fl_str_mv |
2015-06-14T13:39:13Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
Brazilian Journal of Infectious Diseases. Brazilian Society of Infectious Diseases, v. 13, n. 3, p. 191-199, 2009. |
dc.identifier.uri.fl_str_mv |
http://repositorio.unifesp.br/handle/11600/5059 http://dx.doi.org/10.1590/S1413-86702009000300007 |
dc.identifier.issn.none.fl_str_mv |
1413-8670 |
dc.identifier.file.none.fl_str_mv |
S1413-86702009000300007.pdf |
dc.identifier.scielo.none.fl_str_mv |
S1413-86702009000300007 |
dc.identifier.doi.none.fl_str_mv |
10.1590/S1413-86702009000300007 |
dc.identifier.wos.none.fl_str_mv |
WOS:000275105600007 |
identifier_str_mv |
Brazilian Journal of Infectious Diseases. Brazilian Society of Infectious Diseases, v. 13, n. 3, p. 191-199, 2009. 1413-8670 S1413-86702009000300007.pdf S1413-86702009000300007 10.1590/S1413-86702009000300007 WOS:000275105600007 |
url |
http://repositorio.unifesp.br/handle/11600/5059 http://dx.doi.org/10.1590/S1413-86702009000300007 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.none.fl_str_mv |
Brazilian Journal of Infectious Diseases |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
191-199 |
dc.publisher.none.fl_str_mv |
Brazilian Society of Infectious Diseases |
publisher.none.fl_str_mv |
Brazilian Society of Infectious Diseases |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
bitstream.url.fl_str_mv |
${dspace.ui.url}/bitstream/11600/5059/1/S1413-86702009000300007.pdf ${dspace.ui.url}/bitstream/11600/5059/2/S1413-86702009000300007.pdf.txt |
bitstream.checksum.fl_str_mv |
9288cf4a85f38c3c07f6f1715e801e78 ff9be2146f93f3a75c381b3585a20903 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
|
_version_ |
1783460299090690048 |